Targeting tumor cells with bispecific antibodies and T cells

David M Kranz, T. C. Manning, L. A. Rund, B. K. Cho, M. M. Gruber, Edward J Roy

Research output: Contribution to journalArticle

Abstract

It has been known for some time that mammalian immune systems are capable of eliminating large tumor burdens. Redirecting the immune response of a patient to an established tumor has now become the focus of various therapeutic strategies. In this report, two projects toward this goal are described. The first project involves the development of a transgenic mouse model for T cell directed therapeutics. These mice express specific T cell receptor α and β transgenes on a background in which the recombinational- activating-gene-1 (RAG) has been knocked out. The mice express cytotoxic T cells but not either T helper cells or B cells. Despite these deficiencies, the animals are capable of eliminating tumors that express the appropriate peptide/major histocompatibility complex ligand that is recognized by the αβ transgenic T cell receptor. Human tumors grow as transplants in these mice, thereby allowing various agents that redirect the endogenous T cells against human tumors to be tested. The second project involves a description of such agents: bispecific antibodies that simultaneously bind to an immune effector cell and a tumor cell. The bispecific antibody described here consists of folate attached to anti-T cell receptor antibodies, or their fragments. A single-chain Fv coupled with folate can redirect the lysis of human tumor cells that bear the high affinity folate receptor. Preliminary in vivo data showed that the folate/antibody conjugates were also capable of mediating rejection of the human tumor. This transgenic mouse model should now allow the evaluation and optimization of bispecific agents that can redirect a patient's own T cell response.

Original languageEnglish (US)
Pages (from-to)77-84
Number of pages8
JournalJournal of Controlled Release
Volume53
Issue number1-3
DOIs
StatePublished - Apr 30 1998

Fingerprint

Bispecific Antibodies
T-Lymphocytes
Folic Acid
T-Cell Antigen Receptor
Neoplasms
Transgenic Mice
Single-Chain Antibodies
Antibodies
Helper-Inducer T-Lymphocytes
Tumor Burden
Major Histocompatibility Complex
Transgenes
Immune System
B-Lymphocytes
Ligands
Transplants
Peptides
Therapeutics

Keywords

  • Bispecific Antibodies
  • Cytotoxic T Lymphocytes
  • Folate Receptor
  • Transgenic Mice

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Targeting tumor cells with bispecific antibodies and T cells. / Kranz, David M; Manning, T. C.; Rund, L. A.; Cho, B. K.; Gruber, M. M.; Roy, Edward J.

In: Journal of Controlled Release, Vol. 53, No. 1-3, 30.04.1998, p. 77-84.

Research output: Contribution to journalArticle

Kranz, David M ; Manning, T. C. ; Rund, L. A. ; Cho, B. K. ; Gruber, M. M. ; Roy, Edward J. / Targeting tumor cells with bispecific antibodies and T cells. In: Journal of Controlled Release. 1998 ; Vol. 53, No. 1-3. pp. 77-84.
@article{e1584ee53aa0456094b9cd758488f901,
title = "Targeting tumor cells with bispecific antibodies and T cells",
abstract = "It has been known for some time that mammalian immune systems are capable of eliminating large tumor burdens. Redirecting the immune response of a patient to an established tumor has now become the focus of various therapeutic strategies. In this report, two projects toward this goal are described. The first project involves the development of a transgenic mouse model for T cell directed therapeutics. These mice express specific T cell receptor α and β transgenes on a background in which the recombinational- activating-gene-1 (RAG) has been knocked out. The mice express cytotoxic T cells but not either T helper cells or B cells. Despite these deficiencies, the animals are capable of eliminating tumors that express the appropriate peptide/major histocompatibility complex ligand that is recognized by the αβ transgenic T cell receptor. Human tumors grow as transplants in these mice, thereby allowing various agents that redirect the endogenous T cells against human tumors to be tested. The second project involves a description of such agents: bispecific antibodies that simultaneously bind to an immune effector cell and a tumor cell. The bispecific antibody described here consists of folate attached to anti-T cell receptor antibodies, or their fragments. A single-chain Fv coupled with folate can redirect the lysis of human tumor cells that bear the high affinity folate receptor. Preliminary in vivo data showed that the folate/antibody conjugates were also capable of mediating rejection of the human tumor. This transgenic mouse model should now allow the evaluation and optimization of bispecific agents that can redirect a patient's own T cell response.",
keywords = "Bispecific Antibodies, Cytotoxic T Lymphocytes, Folate Receptor, Transgenic Mice",
author = "Kranz, {David M} and Manning, {T. C.} and Rund, {L. A.} and Cho, {B. K.} and Gruber, {M. M.} and Roy, {Edward J}",
year = "1998",
month = "4",
day = "30",
doi = "10.1016/S0168-3659(97)00239-3",
language = "English (US)",
volume = "53",
pages = "77--84",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - Targeting tumor cells with bispecific antibodies and T cells

AU - Kranz, David M

AU - Manning, T. C.

AU - Rund, L. A.

AU - Cho, B. K.

AU - Gruber, M. M.

AU - Roy, Edward J

PY - 1998/4/30

Y1 - 1998/4/30

N2 - It has been known for some time that mammalian immune systems are capable of eliminating large tumor burdens. Redirecting the immune response of a patient to an established tumor has now become the focus of various therapeutic strategies. In this report, two projects toward this goal are described. The first project involves the development of a transgenic mouse model for T cell directed therapeutics. These mice express specific T cell receptor α and β transgenes on a background in which the recombinational- activating-gene-1 (RAG) has been knocked out. The mice express cytotoxic T cells but not either T helper cells or B cells. Despite these deficiencies, the animals are capable of eliminating tumors that express the appropriate peptide/major histocompatibility complex ligand that is recognized by the αβ transgenic T cell receptor. Human tumors grow as transplants in these mice, thereby allowing various agents that redirect the endogenous T cells against human tumors to be tested. The second project involves a description of such agents: bispecific antibodies that simultaneously bind to an immune effector cell and a tumor cell. The bispecific antibody described here consists of folate attached to anti-T cell receptor antibodies, or their fragments. A single-chain Fv coupled with folate can redirect the lysis of human tumor cells that bear the high affinity folate receptor. Preliminary in vivo data showed that the folate/antibody conjugates were also capable of mediating rejection of the human tumor. This transgenic mouse model should now allow the evaluation and optimization of bispecific agents that can redirect a patient's own T cell response.

AB - It has been known for some time that mammalian immune systems are capable of eliminating large tumor burdens. Redirecting the immune response of a patient to an established tumor has now become the focus of various therapeutic strategies. In this report, two projects toward this goal are described. The first project involves the development of a transgenic mouse model for T cell directed therapeutics. These mice express specific T cell receptor α and β transgenes on a background in which the recombinational- activating-gene-1 (RAG) has been knocked out. The mice express cytotoxic T cells but not either T helper cells or B cells. Despite these deficiencies, the animals are capable of eliminating tumors that express the appropriate peptide/major histocompatibility complex ligand that is recognized by the αβ transgenic T cell receptor. Human tumors grow as transplants in these mice, thereby allowing various agents that redirect the endogenous T cells against human tumors to be tested. The second project involves a description of such agents: bispecific antibodies that simultaneously bind to an immune effector cell and a tumor cell. The bispecific antibody described here consists of folate attached to anti-T cell receptor antibodies, or their fragments. A single-chain Fv coupled with folate can redirect the lysis of human tumor cells that bear the high affinity folate receptor. Preliminary in vivo data showed that the folate/antibody conjugates were also capable of mediating rejection of the human tumor. This transgenic mouse model should now allow the evaluation and optimization of bispecific agents that can redirect a patient's own T cell response.

KW - Bispecific Antibodies

KW - Cytotoxic T Lymphocytes

KW - Folate Receptor

KW - Transgenic Mice

UR - http://www.scopus.com/inward/record.url?scp=0032580490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032580490&partnerID=8YFLogxK

U2 - 10.1016/S0168-3659(97)00239-3

DO - 10.1016/S0168-3659(97)00239-3

M3 - Article

C2 - 9741915

AN - SCOPUS:0032580490

VL - 53

SP - 77

EP - 84

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1-3

ER -